Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Obese Subjects.

NCT05433506 is registered in ClinicalTrials.gov with Rivus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05433506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05433506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Obese Subjects.
Lead sponsor
Rivus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2022
Completion date
March 15, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obese